In our literature review, we analyzed the role of CA125 and HE4 as potential serum biomarkers for the diagnosis and prognosis of leiomyosarcomas, highlighting conflicting data and a still limited use in clinical practice. The gene discussed is MUC16; the disease is leiomyosarcoma.